TY  - JOUR
AU  - Myacheva, Ksenia
AU  - Walsh, Andrew
AU  - Riester, Marisa
AU  - Pelos, Giulia
AU  - Carl, Jane
AU  - Diederichs, Sven
TI  - CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway.
JO  - Cancer letters
VL  - 552
IS  - 1
SN  - 0304-3835
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2022-02452
SP  - 215958
PY  - 2023
N1  - #EA:B150#LA:B150# / 2023 Jan 1;552:215958
AB  - Since lung cancer remains the leading cause of cancer death globally, there is an urgent demand for novel therapeutic targets. We carried out a CRISPR interference (CRISPRi) loss-of-function screen for human lung adenocarcinoma (LUAD) targeting 2098 deregulated genes using a customized algorithm to comprehensively probe the functionality of every resolvable transcriptional start site (TSS). CASP8AP2 was identified as the only hit that significantly affected the viability of all eight screened LUAD cell lines while the viability of non-transformed lung cells was only moderately impacted. Knockdown (KD) of CASP8AP2 induced both autophagy and apoptotic cell death pathways. Systematic expression profiling linked the AP-1 transcription factor to the CASP8AP2 KD-induced cancer cell death. Furthermore, inhibition of AP-1 reverted the CASP8AP2 silencing-induced phenotype. Overall, the tailored CRISPRi screen profiled the impact of over 2000 genes on the survival of eight LUAD cell lines and identified the CASP8AP2 - AP-1 axis mediating lung cancer viability.
KW  - Autophagy (Other)
KW  - CRISPR (Other)
KW  - Caspase (Other)
KW  - FLASH (Other)
KW  - Lung adenocarcinoma (Other)
KW  - NSCLC (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36252816
DO  - DOI:10.1016/j.canlet.2022.215958
UR  - https://inrepo02.dkfz.de/record/182135
ER  -